CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia  


You May Also Like

Psoria-Shield, Inc. Expands Relationship with Prominent Healthcare Organization

HOFFMAN ESTATES, IL, June 19, 2018 (GLOBE NEWSWIRE) -- Wellness Center USA, Inc. (OTCQB: WCUI), ...

Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma

MADISON, Wis., July 09, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical ...